Enjoy complimentary customisation on priority with our Enterprise License!
The enzyme-linked immunosorbent assay (Elisa) testing market size is estimated to grow by USD 564.97 million at a CAGR of 13.6% between 2022 and 2027. The growth of the market depends on several factors, including the growing need for frequent diagnostic testing among the aging population, the rise in toxicology testing in the food industry, and the increase in chronic diseases.
To learn more about this report, Download Sample PDF
The increase in chronic diseases is notably driving the market growth, although factors such as a lack of trained professionals may impede the market growth. Our researchers analyzed the data with 2022 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.
The increase in chronic diseases is the key factor driving the global market growth. Chronic diseases are one of the major causes of disability and death across the world. Four major chronic diseases are CVDs, cancer, chronic obstructive pulmonary disease, and type 2 diabetes, which occur due to high blood pressure, high blood cholesterol, and overweight, as well as due to unhealthy diet, physical inactivity, and tobacco use. These conditions are accelerating disease rates globally and pervading all socioeconomic classes.
Elisa tests can not only help to diagnose a disease but also manage the illness. A test result helps a doctor to assess the severity of the disease, estimate the patient's prognosis, monitor the course of disease progression, stability or resolution, detect relapse, and select drugs or adjust therapy, thus increasing the demand for Elisa testing in the diagnosis of patients, which will drive the growth of the market during the forecast period.
The growing importance of promotional activities is one of the major market trends. The nature of the product, coupled with the niche end-user market, makes it difficult for companies to market these products. Unlike other assays, brand and product visibility have a limited role in the sale of Elisa tests. Emphasis is on improving the distribution network and increasing the availability of products to end-users. Advertising and marketing of these products are restricted. Also, there has been a significant lack of awareness about such products. However, leading Companies have recognized this issue and hence are promoting the use of Elisa testing through their websites.
To help end-users, Thermo Fisher Scientific offers additional support materials such as the explanation of techniques through pdf documents and brochures as well as interactive videos on YouTube. In addition, non-profit research organizations in Europe are conducting annual workshops in partnership with pharma companies to enhance awareness about Elisa tests for the early detection of diseases. As product enhancements continue in the market, Companies are beginning to realize the importance of promotional activities. This trend is set to pick up in the market and eventually support market growth during the forecast period.
The stringent government regulations are a major challenge to the global market growth. The commercialization of diagnostic products is challenging as some products are classified as medical devices as they are used by physicians for diagnostic purposes. Such devices cannot be marketed without successfully completing clinical trials, which is a time-consuming, expensive, and uncertain process. Regulations for the approval of these devices vary from one country to another, which is a major challenge faced by multinational companies. In addition, any changes in regulations by different governing bodies, such as the FDA, during product development could delay the launch of potential products.
Many developed countries such as the US, the UK, Germany, France, Japan, Singapore, and South Korea have stringent regulations for the approval and marketing of diagnostic products. As these are high-income countries, the high cost of clinical trials and product launches increases the expenditure for Companies. Hence, many small companies and startup biotechnology companies seek government or private funding. However, most organizations provide limited funds to Companies. Thus, stringent government regulations in different countries will affect the development of Elisa testing products.
The market growth analysis report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the market growth and forecasting report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their growth strategies.
Customer Landscape
Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market.
Abbott - The company offers enzyme-linked immunosorbent assays such as PBS Buffer for Forensic Matrices
The market research and growth report also includes detailed analyses of the competitive landscape of the market and information about 15 market Companies, including:
Qualitative and quantitative analysis of Companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize Companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize Companies as dominant, leading, strong, tentative, and weak.
The market share growth by the vaccine development segment will be significant during the forecast period. In this segment the assay technique determines the immune activity against the vaccine. These essays are usually paired along with possible inhibition assays to study the immune response to the growth of the pathogen. Elisa is one of the ligand-binding techniques that is often used to assess the humoral response to the vaccine candidate. This assay technique relies on the formation of an immune complex between the antibody and antigen. Elisa is widely used in the vaccine development process for determining the immune response toward a vaccine and to analyze the efficacy of the vaccine in preclinical stages.
Get a glance at the market contribution of various segments Request Market Research Report Sample PDF
The vaccine development segment was valued at USD 90.99 million in 2017 and continue to grow by 2021. Vaccine development and testing is a long and intensive process, including several stages, starting with an exploratory stage to identify antigens. Next, A vaccine candidate's immunogenicity and safety are assessed using animal models and preclinical cell cultures. Following the approval of an Investigational New Drug application to the US Food and Drug Administration, clinical trials begin. During the preclinical and early phases of the clinical trial, various assays are developed and validated. These assays have to pass well-characterized parameters and criteria before lot release. Eventually, a successful vaccine candidate passes through to Phase III trials to be licensed. The entire vaccine development and testing process can take more than 15 years to complete. Such factors will increase the market growth during the forecast period.
For more insights on the market share of various regions Request Market Research Report Sample PDF
North America is estimated to contribute 36% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period. North America is a dominating region in the global market, with the US and Canada as the leading revenue-generating countries. Increasing demand for timely and accurate diagnosis of infectious and chronic diseases and the presence of several pharmaceutical companies in the US and Canada that are focusing on drug development is driving the adoption of Elisa testing in the region.
The Enzyme-linked immunosorbent assay (ELISA) market is propelled by its versatility in detecting antibodies, biomarkers, and infectious conditions, offering cost-effective technologies for ailment diagnosis and chronic illnesses management. Automation enhances testing efficiency, with ELISA assays being widely utilized in the drug discovery domain and research applications. Multiplex proteomic array platforms enable precise protein quantification and virus testing, while sandwich ELISA remains a cornerstone in infectious diseases applications like HIV and Lyme disease diagnosis. Market growth is driven by continuous flow technology and portable ELISA devices, promising significant expansion in revenue, particularly in cancer diagnostics and immunoassays, reflecting increasing health awareness and demand for innovative disease diagnosis tools.
The market forecasting report forecasts market growth by revenue at global, regional & country levels and provides an analysis of the latest trends and growth opportunities from 2017 to 2027.
Enzyme-linked Immunosorbent Assay (Elisa) Testing Market Scope |
|
Report Coverage |
Details |
Page number |
178 |
Base year |
2022 |
Historic period |
2017-2021 |
Forecast period |
2023-2027 |
Growth momentum & CAGR |
Accelerate at a CAGR of 13.6% |
Market growth 2023-2027 |
USD 564.97 million |
Market structure |
Fragmented |
YoY growth 2022-2023(%) |
13.26 |
Regional analysis |
North America, Europe, Asia, and Rest of World (ROW) |
Performing market contribution |
North America at 36% |
Key countries |
US, UK, Germany, China, and Japan |
Competitive landscape |
Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks |
Key companies profiled |
Abbott Laboratories, Abcam plc, Agilent Technologies Inc., Amgen Inc., Avantor Inc., Becton Dickinson and Co., Bio Rad Laboratories Inc., bioMerieux SA, Cardinal Health Inc., Crux Biolabs Pty Ltd., Danaher Corp., Eppendorf SE, Illumina Inc., Lonza Group Ltd., Merck KGaA, Novo Nordisk AS, Perkin Elmer Inc, QIAGEN NV, Siemens Healthineers AG, and Thermo Fisher Scientific Inc. |
Market dynamics |
Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, Market condition analysis for forecast period. |
Customization purview |
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
Request Market Research Report Sample PDF
We can help! Our analysts can customize this market report to meet your requirements. Get in touch
Get lifetime access to our
Technavio Insights
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.